InvestorsHub Logo
Followers 19
Posts 719
Boards Moderated 0
Alias Born 12/21/2012

Re: None

Saturday, 06/28/2014 1:22:56 PM

Saturday, June 28, 2014 1:22:56 PM

Post# of 11554
CTIX DD-Catalysts-Brilicidin-Anitbiotic Wonderdrug?
Possible BTD for B-Defensin Mimetic Antibiotic-No human resistance. If B rivals Daptomycyn and the mechanism of action does not allow for resistance-WATCH OUT!

July 2014-Possible PR's

1. B-ABSSSI interim report
2. B-ABSSSI enrollment complete
3. B-OM INDA
4. K cohort 8 dosing start
5. P phase 1 report

Resistance to Daptomycin is on the rise as the usage of this antibiotic increases.

http://cid.oxfordjournals.org/content/40/7/1058.long

Brilacidin PR within 1-2 weeks after the interim data is collected. Possible BTD before year end.

We know from the phase 2 B Polymedix data that all 3 arms produced significant clinical results for skin and soft tissue infections.

This new class of antibiotics, in which Brilacidin is the prototype should not be subject to bacterial resistance.

For this reason alone, Brilacidin may shoot to drug of choice status.


"* Kevetrin Phase 1 entering 8th Cohort with no prior phase 1 limiting DLTs or MTD yet observed. Dosing now into the higher of the anticipated efficacy range. Cohort 8 215MG, 33% increase. Possible MTD by cohort 9/10

* K in combination against renal completed most if not all preclinical work done.
* K in combination against leukemia (AML) already [completed] preclinical work at UofB and a Phase 1b/2 Clinical Trial is poised to start
* K against Retinoblastoma announced in March 2013 will commence soon
* Prurisol bridge study enrollment complete. Abracavir conversion will result in phase 2/3
* B against ABSSSI now 70% enrolled and treated NO AE's.

* Large pharma discussions underway possible announcement after July review board meeting. Possible BTD on B after review meeting or by end of trial if results match or beat Daptomycyn

* B OM completed final formulation work and expected to submit INDA to FDA.
* B ocular formulation studies underway at Dr Reddy's and should complete within the next few to 6 months.
* B otic also in formulation studies at Dr Reddy's
* B DFI just announced high efficacy and should begin final preclinical work ahead of clinical testing. "
*B NY/ NJ universities material transfer agreement defensive mimetics
*Cellceutix in June, 2014, entered into a research agreement with a renowned non-profit research institution for studies of anti-fungal compounds in Cellceutix’s portfolio. The research is to be funded by a $1.5 million grant from the National Institute of Health, Small Business Innovation Research (SBIR) to the non-profit institution

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.